Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea, and even disturbed vision in some cases.

Increase in prevalence of migraine, rapid rise in female population, and surge in awareness among patients for migraine treatment & prevention drive the growth of the global migraine drugs market. However, the side effects of migraine drugs are expected to limit market growth. Conversely, emerging new therapies/drugs for migraine treatment and growth opportunities in the emerging nations are expected to present opportunities for market growth during the forecast period.

The market was valued at $1,713 million in 2017 and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period.

Download Sample @ www.alliedmarketresearch.com/request-sample/2811?utm_sour...

By type, abortive medicines accounted for more than three-fourths share of the global migraine drugs market in 2017. Furthermore, by route of administration, the oral segment is anticipated to grow at the highest rate of 3.4% during the forecast period.

Key Findings of the Migraine Drugs Market:

• North America occupied a two-fifths share of the global migraine drugs market.
• Oral is anticipated to grow with the highest CAGR throughout the forecast period.
• Europe is anticipated to occupy more than one-fourth market share of the global migraine drugs market by 2025.
• Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

Major Players:

• AstraZeneca
• Eisai Co. Ltd.
• Endo International Plc.
• GlaxoSmithKline Plc.
• Impax Laboratories
• Johnson & Johnson
• Merck & Co.
• Pfizer Inc.

North America was the leading revenue contributor to the global market in 2017, owing to a surge in demand for better healthcare along with effective government reforms for awareness towards migraine & its prevention. However, Asia-Pacific is expected to grow at the highest CAGR of 4.4% from 2018 to 2025, due to improvements in healthcare infrastructure and rise in demand for better healthcare facilities.

Flat 20% Discount on All License Type...
https://www.alliedmarketresearch.com/checkout/657755?utm_source=openpr_ss

* Offer Valid Till 20th April 2019

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.